Log In
Sign Up
MorphoSys’ Phase 3 Study of Pelabresib in Myelofibrosis Demonstrates Statistically Significant Improvement in Spleen Volume Reduction and Strong Positive Trend in Symptom Reduction
morphosys.com
Post by
|
1 points
|
Nov 21, 2023
|
Add Comment
About
FAQ
Legal
Contact
© 2023-24 DxMultiomics. All rights reserved.
